ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
China Pharma Holdings Inc

China Pharma Holdings Inc (CPHI)

0.1976
-0.0223
( -10.14% )
Updated: 11:19:26

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.1976
Bid
-
Ask
-
Volume
204,689
0.197501 Day's Range 0.215
0.13 52 Week Range 0.599
Market Cap
Previous Close
0.2199
Open
0.215
Last Trade
1
@
0.1975
Last Trade Time
11:19:26
Financial Volume
$ 41,557
VWAP
0.203024
Average Volume (3m)
866,041
Shares Outstanding
19,253,363
Dividend Yield
-
PE Ratio
-1.31
Earnings Per Share (EPS)
-0.16
Revenue
7.03M
Net Profit
-3.08M

About China Pharma Holdings Inc

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic ... China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Carson City, Nevada, USA
Founded
-
China Pharma Holdings Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker CPHI. The last closing price for China Pharma was $0.22. Over the last year, China Pharma shares have traded in a share price range of $ 0.13 to $ 0.599.

China Pharma currently has 19,253,363 shares outstanding. The market capitalization of China Pharma is $4.23 million. China Pharma has a price to earnings ratio (PE ratio) of -1.31.

CPHI Latest News

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville PR Newswire HAIKOU, China, Dec. 18, 2024 HAIKOU, China, Dec. 18, 2024 /PRNewswire/...

China Pharma Announces the Entry of "At-The-Market" Equity Offering

China Pharma Announces the Entry of "At-The-Market" Equity Offering PR Newswire HAIKOU, China, Dec. 13, 2024 HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc...

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 PR Newswire HAIKOU, China, Aug. 19, 2024 HAIKOU, China, Aug. 19, 2024...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0324-14.08695652170.230.3350.192249208670.27139378CS
40.007640.190.3350.1321423860.24225411CS
12-0.0514-20.64257028110.2490.3350.138660410.2356294CS
26-0.0524-20.960.250.3350.135507600.23462305CS
52-0.3024-60.480.50.5990.137275990.3486209CS
156-21.4224-99.086031452421.6226.30.139999362.84970467CS
260-18.8024-98.961981.50.13125157220.12746129CS

CPHI - Frequently Asked Questions (FAQ)

What is the current China Pharma share price?
The current share price of China Pharma is $ 0.1976
How many China Pharma shares are in issue?
China Pharma has 19,253,363 shares in issue
What is the market cap of China Pharma?
The market capitalisation of China Pharma is USD 4.23M
What is the 1 year trading range for China Pharma share price?
China Pharma has traded in the range of $ 0.13 to $ 0.599 during the past year
What is the PE ratio of China Pharma?
The price to earnings ratio of China Pharma is -1.31
What is the cash to sales ratio of China Pharma?
The cash to sales ratio of China Pharma is 0.58
What is the reporting currency for China Pharma?
China Pharma reports financial results in USD
What is the latest annual turnover for China Pharma?
The latest annual turnover of China Pharma is USD 7.03M
What is the latest annual profit for China Pharma?
The latest annual profit of China Pharma is USD -3.08M
What is the registered address of China Pharma?
The registered address for China Pharma is 321 W WINNIE LN, STE 104, CARSON CITY, NEVADA, 89703
What is the China Pharma website address?
The website address for China Pharma is www.chinapharmaholdings.com
Which industry sector does China Pharma operate in?
China Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAPAKairos Pharma Ltd
$ 1.9199
(97.93%)
40.09M
TPETTrio Petroleum Corp
$ 2.60
(35.42%)
5.28M
EONREON Resources Inc
$ 1.105
(20.11%)
5.23M
HUSAHouston American Energy Corp
$ 1.9405
(15.51%)
651.92k
ROLRHigh Roller Technologies Inc
$ 3.89
(15.09%)
54.66k
LODEComstock Inc
$ 0.2794
(-47.28%)
23.99M
AEONAEON Biopharma Inc
$ 0.1344
(-27.59%)
13.51M
OPTTOcean Power Technologies Inc
$ 0.8692
(-24.42%)
20.18M
CTMCastellum Inc
$ 0.7869
(-24.34%)
3.91M
MRNYYieldmax Mrna Option Income Strategy ETF
$ 3.99
(-19.72%)
1.09M
KAPAKairos Pharma Ltd
$ 1.905
(96.39%)
40.09M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 26.9249
(-4.05%)
38.22M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
$ 6.5801
(1.86%)
28.76M
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 8.5195
(-8.00%)
27.96M
LODEComstock Inc
$ 0.2794
(-47.28%)
23.99M

CPHI Discussion

View Posts
maestro_of_Ihub maestro_of_Ihub 4 days ago
Word is maestro posse gonna light this up in PM again! 💪🏿😈👀🍿
πŸ‘οΈ0
glenn1919 glenn1919 7 days ago
cphi.......................................................a/h
👍️ 1
heyitsmeagain heyitsmeagain 3 months ago
Moves big coming 
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
15 million you mean?
πŸ‘οΈ0
maestro_of_Ihub maestro_of_Ihub 8 months ago
Wow talk about nightmare earnings! Share outstanding went from 1 million to 13 million! Company in serious risk of filing bankruptcy at this point! Nothing on DED or anything else positive! Wish I never saw this garbage!
πŸ‘οΈ0
Topgun21 Topgun21 8 months ago
Trend is your friend!! $CPHI
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
.35s after hours
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
.31s filling loading before news drops GL if your playing & holding :D
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
.34s p/m
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
1 month left of 1st half 2024 news could drop anyday on 1 million float insiders own 86%

Quote from 2023 news β€”>

Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year.




2023 news below

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html

SOURCE China Pharma Holdings, Inc.


Copyright 2023 PR Newswire
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
.32 chart -> https://schrts.co/NCwWJCPg
πŸ‘οΈ0
stock1ace1 stock1ace1 8 months ago
Watch for news to drop 1 mill float now after r/s in march

QUOTE
β€œβ€We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”


after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*

Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d






News β€”> 11/29/23

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html

SOURCE China Pharma Holdings, Inc.


Copyright 2023 PR Newswire
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
CPHI new 52 lo
πŸ‘οΈ0
PennyPusher786 PennyPusher786 10 months ago
No I mean days later when you look at the chart, and I'm using it on the mobile app... perhaps it's a different set up online.

But ihub on the mobile app doesn't show you the high of the day on the chart when you look back up to 3 years. It shows the Closing price.

Like I said, perhaps it's different on the desktop app
πŸ‘οΈ0
lucky, mydog lucky, mydog 11 months ago
ihub doesn't show the high of day

sure it does.

https://ih.advfn.com/stock-market/AMEX/china-pharma-CPHI/stock-price
πŸ‘οΈ0
Renee Renee 11 months ago
CPHI: effective March 6,2024 a one for 5 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
πŸ‘οΈ0
81vette 81vette 11 months ago
So far so good,no r/s today at least(usually immediately after close,4pm)
πŸ‘οΈ0
81vette 81vette 11 months ago
https://www.bing.com/search?q=why+do+companies+file+an+S-3+notice+of+effectiveness&qs=n&form=QBRE&sp=-1&lq=0&pq=why+do+companies+file+an+s-3+notice+of+effectiveness&sc=6-52&sk=&cvid=EC657C8D81EE4DA088E54A28A79C767C&ghsh=0&ghacc=0&ghpl=
πŸ‘οΈ0
81vette 81vette 11 months ago
just noticed it trades on amex exchange,thats the otc of big boards imo
πŸ‘οΈ0
81vette 81vette 11 months ago
always go with your gut,trusting a china ticker is like trusting a fart,sometimes you get shit on,lol
πŸ‘οΈ0
eyeownu eyeownu 11 months ago
would like to take a position but somethings says WAIT
πŸ‘οΈ0
81vette 81vette 11 months ago
AGBA private placement closed 3 hrs ago,shares ava. to short dropping,charting bullish,looking good!!!
πŸ‘οΈ0
PennyPusher786 PennyPusher786 11 months ago
Personally, I think better odds on the Chinese ticker $AGBA
πŸ‘οΈ0
PennyPusher786 PennyPusher786 11 months ago
Makes sense, I always forget, ihub doesn't show the high of day, just the close... lol silly me...

Good luck... sometimes reverse Splits bank big... depends whose involved
πŸ‘οΈ0
81vette 81vette 11 months ago
1 for10 r/s was approved in dec.can be effected anytime,it could be coming after close today,i wont be holding thru close just in case
👍️ 1
81vette 81vette 11 months ago
it went from lod .11 to hod .23,but yea 100m vol @.15 ave=$15m,i would expect a much bigger move from that much vol,must have been a bunch of debt paid off that day,or dark pool crooked mms,a 1 for 10 r/s was approved in dec. and it says can be effected anytime,could be effective after close,the effect today doesnt say what it is,but i wont be holding thru close today just incase
πŸ‘οΈ0
PennyPusher786 PennyPusher786 11 months ago
In December, they had 100 million volume, but they only moved from .10 - .13 cents... 30% is still an amazing win I guess
πŸ‘οΈ0
81vette 81vette 11 months ago
http://www.chinapharmaholdings.com/
πŸ‘οΈ0
81vette 81vette 11 months ago
maybe urine lol,the last 8k filing was a definitive material agreement for patent purchase of a psoriasis product,maybe its poop lol ,they paid 15m shares and 5m restricted ($2M) and 10% of profit for 10 years
πŸ‘οΈ0
Triple nickle Triple nickle 11 months ago
What’s the dry eye devise a bottle of visine. CPHI
πŸ‘οΈ0
81vette 81vette 11 months ago
https://capedge.com/filing/1106644/9999999995-24-000463/CPHI-EFFECT ,usually comes with 8k detail filing of what effect occurred,this 13g filed yesterday, the last filing was definitive agreement of patent transfer,maybe that has taken effect> https://capedge.com/filing/1106644/0001213900-24-011587/CPHI-8K
πŸ‘οΈ0
81vette 81vette 11 months ago
haven't ran since nov,oversold,poked head above ma's today(hint of bullish start)with china hype lately and .10pps i think its a prime suspect for interest,and if the expected merger news hits it should do well
πŸ‘οΈ0
81vette 81vette 11 months ago
sales 7.78m,book .21,mkt cap 5.57m,float 21m,o/s 57m
πŸ‘οΈ0
81vette 81vette 11 months ago
ran to .2310 on nov 29th with 105m traded
πŸ‘οΈ0
81vette 81vette 11 months ago
shares ava. to short is high 800k,has dropped to zero borrow before with vol.,but who in right mind shorts from a dime
πŸ‘οΈ0
81vette 81vette 11 months ago
china runner starting!!!
πŸ‘οΈ0
CarlCarlMcB CarlCarlMcB 11 months ago
Rock on Fish on start reeling $$$$$$
πŸ‘οΈ0
maestro_of_Ihub maestro_of_Ihub 12 months ago
So the Taylor Swift of China now owns 15 million shares of this? https://en.wikipedia.org/wiki/Liu_Tao
πŸ‘οΈ0
maestro_of_Ihub maestro_of_Ihub 12 months ago
So the Taylor Swift of China now owns 15 million shares of this? https://en.wikipedia.org/wiki/Liu_Tao
πŸ‘οΈ0
Invest-in-America Invest-in-America 12 months ago
CPHI: Got some of this Chinese Un-Fortunate-Cookie @$0.1255 in the Post-M today, for my personal amusement. ("Mark's" mention on the Orions Board, due filings just now; even though he HATES it.)


PS: I got married AGAIN, last Sunday, in a local San Diego Atheists' Chapel! Check-out a clip from the ceremony, above!! She's a veritable DOLL, ain't she??!! We're flyin' to PALESTINE for our honeymoon!! Booked a nice suite in a Motel-6 there, in the Golan Heights, run by a Jewish buddy of mine!!
πŸ‘οΈ0
TheFinalCD TheFinalCD 12 months ago
i WONDER IF THIS IS THE SAME GUY

https://www.propublica.org/article/liu-tao-trump-meeting-china-investigation
https://ih.advfn.com/stock-market/AMEX/china-pharma-CPHI/stock-news/93151163/form-sc-13g-statement-of-acquisition-of-benefici


CPHI January 2024 Shelf
EDGAR
Pending Effect

Current Raisable Amount
$16,532,168
Total Shelf Capacity
$50,000,000


https://dilutiontracker.com/app/search/CPHI?a=dbb88c
πŸ‘οΈ0
Tyrus603 Tyrus603 1 year ago
"Fake news?" Congrats to all you CPHI shareholders on your incoming 33,000 % gains!

CNN financials page analyst says "price target $45. Revenues $37M. EPS $2+."

But the NYSE stock's actually trading at 13 cents and market cap of $4M?

WTAF is true anymore?

https://money.cnn.com/quote/quote.html?symb=CPHI#:~:text=China%20Pharma%20Holdings%20Inc%20(NYSE%20American%3ACPHI)

https://twitter.com/tyrus603/status/1732100139550965843?t=DoOtwX4vmgUKX8MPn5oKtg&s=19
πŸ‘οΈ0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 1 year ago
$CPHI ~ China Pharma Holdings Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

Link: https://finance.yahoo.com/news/china-pharma-holdings-inc-announced-130000348.html

$$$CPHI$$$
πŸ‘οΈ0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 1 year ago
Form_4 filing shows Li Zhilin as the owner of 15,138,063 $CPHI shares. WOW!

https://www.otcmarkets.com/filing/html?id=16995596&guid=WuJ-kahrG2lS-ch#OWNERSHIP_HTM_F1
πŸ‘οΈ0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 1 year ago
$CPHI >>> 1Y/Daily Chart~



$$$CPHI$$$
πŸ‘οΈ0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 1 year ago
$CPHI ~ 180day/daily Chart~



$$$CPHI$$$
πŸ‘οΈ0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 1 year ago
$CPHI ~ China Pharma Holdings Inc @$.13
+0.0051 (+4.08%)
Volume: 2,905,839
Day Range: 0.125 - 0.142
Last Trade Time: 5:48:57 PM EST




$$$CPHI$$$
πŸ‘οΈ0
webprods webprods 1 year ago
Buyout ?
πŸ‘οΈ0
maestro_of_Ihub maestro_of_Ihub 1 year ago
45 cents works for me!
πŸ‘οΈ0
webprods webprods 1 year ago
Patience will bring $45 per share here.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock